Analysis of whether Lurbinectedin has been included in medical insurance and reimbursement policies

Lurbinectedin (Lurbinectedin) is a new type of anti-tumor drug that belongs to the DNA binding inhibitor class of chemotherapy drugs. It is mainly used to treat metastatic small cell lung cancer (SCLC) and other specific solid tumors. The drug has been officially launched in the country, providing patients with new treatment options. However, due to the short time on the market, sales channels and pricing in the domestic market are not yet fully transparent, and patients need to obtain drugs through regular hospital pharmacies or authorized channels.

Up to now, Rubicatin has not been included in the national medical insurance directory in China, so patients need to purchase it at their own expense when using it. The domestic listing price information is not yet clear, but based on Hong Kong market data, 4mg each box is priced at approximately 2 more than RMB (exchange rate fluctuations may cause price changes). Since medical insurance does not cover it, patients pay higher out-of-pocket treatment costs. Especially for patients who require long-term or continuous courses of treatment, the financial pressure is greater.

In overseas markets, there are mainly two types of Rubicatin original drugs: the US version and the Singapore version. The price of the US version is about more than 90,000 RMB per box, and the price of the Singapore version is about more than 30,000 RMB per box. Currently, there are no generic drugs of Rubicatin on the market overseas. For domestic patients, if they purchase through formal cross-border medical channels, factors such as drug transportation, customs clearance and regulatory policies need to be considered, and the cost is still high.

Since Rubicatin is not included in medical insurance and patients pay a high proportion of their own expenses, it is recommended to communicate with the hospital and the medical insurance department before treatment to understand whether there is a possibility of supplementary medical insurance or commercial insurance reimbursement. In addition, patients can pay attention to clinical trial projects or pharmaceutical companies’ patient assistance programs (PAP). Some projects can provide free or discounted drugs to help reduce financial burden. For patients with limited financial conditions, it is very important to reasonably plan the course of treatment and medication, and to choose the most suitable treatment strategy under the guidance of a doctor.

Reference materials:https://www.drugs.com/